EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use

Claudio Bilato, Roberto Baratta, Leonardo De Luca, Maurizio De Luca, Alessandro Fucili, Massimo Iacoviello, Paolo Sbraccia, Luca Busetto

Nutrition, Metabolism and Cardiovascular Diseases · 2026-12 · 36 (12) · 104872

DOI: 10.1016/j.numecd.2026.104872 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2026-12. Verfasst von Claudio Bilato und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, West Vicenza General Hospitals, Arzignano, Vicenza, Italy. Electronic address: claudio.bilato@aulss8.veneto.it. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Obesity, Glucagon-Like Peptides, Anti-Obesity Agents. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Overweight and obesity are major global health challenges and key drivers of cardiovascular disease (CVD), yet patients with established CVD and excess body weight remain systematically under-recognized and undertreated. This consensus paper, developed by an Italian multidisciplinary panel of cardiology, endocrinology and obesity experts, aims to characterize the clinical phenotype of CVD patients most likely to benefit from semaglutide therapy, identify barriers to its implementation, and propose patient-centered strategies to optimize treatment pathways. DATA SYNTHESIS: The document reviews the pathophysiological relevance of adiposity in cardiovascular risk, and discusses the evolving diagnostic framework beyond body mass index (e.g., waist-to-height ratio). Evidence from SELECT trial is contextualized to support semaglutide as a disease-modifying therapy with benefits largely independent of weight loss. The expert panel highlights persistent barriers related to reimbursement, organizational limitations, cultural bias, and therapeutic inertia. To address these gaps, a flexible multidisciplinary care model is proposed, centered on systematic patient identification, shared follow-up responsibilities among cardiologists, general practitioners and obesity specialists, structured clinical pathways, and digital or automated tools to reduce missed opportunities for treatment. Emphasis is placed on consistent clinician education and patient empowerment as essential components for long-term adherence and cardiometabolic risk reduction. CONCLUSIONS: Integrating semaglutide into routine cardiovascular care requires a coordinated, patient-centered approach supported by specialty networking, aligned educational frameworks, and organizational tools to streamline identification, initiation, and monitoring. Implementing these strategies can strengthen secondary prevention, reduce therapeutic inertia, and ensure that patients with CVD and excess adiposity receive timely, evidence-based, and holistic management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesObesityGlucagon-Like PeptidesAnti-Obesity AgentsAdiposityWeight LossHumansSemaglutideTreatment OutcomeConsensusRisk AssessmentHeart Disease Risk Factors

Substanzen

SemaglutideGlucagon-Like PeptidesAnti-Obesity Agents

Autor:innen und Institutionen

  • Division of Cardiology, West Vicenza General Hospitals, Arzignano, Vicenza, Italy. Electronic address: claudio.bilato@aulss8.veneto.it.
  • Endocrine Unit, Garibaldi Hospital, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
  • Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Department of Emergency, General and Bariatric Surgery, Rovigo Hospital, Rovigo, Italy.
  • Cardiology Department, Arcispedale Sant'Anna, Ferrara, Italy.
  • Department of Medical and Surgical Sciences, University of Foggia, Italy.

Zitieren

APA

Bilato, C., Baratta, R., De Luca, L., De Luca, M., Fucili, A., Iacoviello, M., Sbraccia, P., & Busetto, L. (2026). Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use. Nutrition, Metabolism and Cardiovascular Diseases, 36(12), 104872. https://doi.org/10.1016/j.numecd.2026.104872

Vancouver

Bilato C, Baratta R, De Luca L, De Luca M, Fucili A, Iacoviello M, et al. Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use. Nutrition, Metabolism and Cardiovascular Diseases. 2026;36(12):104872. doi:10.1016/j.numecd.2026.104872

BibTeX
@article{Bilato2026,
  author = {Bilato, Claudio and Baratta, Roberto and De Luca, Leonardo and De Luca, Maurizio and Fucili, Alessandro and Iacoviello, Massimo and Sbraccia, Paolo and Busetto, Luca},
  title = {Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use},
  journal = {Nutrition, Metabolism and Cardiovascular Diseases},
  year = {2026},
  volume = {36},
  number = {12},
  pages = {104872},
  doi = {10.1016/j.numecd.2026.104872}
}
Kostenlos starten →